<DOC>
	<DOCNO>NCT02797067</DOCNO>
	<brief_summary>The purpose study determine whether rectal indomethacin reduces incidence post-ESWL pancreatitis .</brief_summary>
	<brief_title>Rectal Indomethacin Prevent Post ESWL-pancreatitis</brief_title>
	<detailed_description>It prospective , double-blind , randomize control trial . Patients painful chronic pancreatitis pancreatic stone ( &gt; 5 mm diameter ) treat ESWL Changhai Hospital randomly allocate indomethacin placebo therapy procedure .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>patient painful chronic pancreatitis pancreatic stone ( &gt; 5 mm diameter ) undergo PESWL least 18 year old provide informed consent contraindication ESWL suspect establish malignancy pancreatic ascites receive NSAIDs within 7 day contraindication NSAIDs ( include gastrointestinal hemorrhage within 4 week renal dysfunction serum creatinine &gt; 120 Î¼mol/L ) presence coagulopathy receive anticoagulation therapy within 3 day acute pancreatitis within 3 day know active cardiovascular cerebrovascular disease pregnant breastfeed woman without rectum ( ie , status posttotal proctocolectomy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Extracorporeal Shock Wave lithotripsy ( ESWL )</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Chronic pancreatitis</keyword>
</DOC>